Kobayashi Pharmaceutical Co., Ltd. provided earnings guidance for the full year of 2022. The company expected to achieve sales target with a little margin, but on the profit side, the company have not achieved cost reduction plan, raw material prices continue to rise, and fixed and distribution costs are increasing. In response, will work to achieve projected operating income while curbing advertising expenses and reducing other costs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,308 JPY | -1.74% | +1.63% | -21.83% |
06-24 | Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) dropped from S&P Japan Mid Cap 100 | CI |
05-24 | Japan companies hog the spotlight as hedge funds tout their top Asia picks | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.83% | 2.46B | |
+12.74% | 390B | |
+21.75% | 79.62B | |
-4.36% | 71.68B | |
-27.28% | 38.13B | |
-14.96% | 35.06B | |
+0.41% | 33.01B | |
+9.36% | 18.3B | |
+21.45% | 16.83B | |
+8.84% | 12.87B |
- Stock Market
- Equities
- 4967 Stock
- News Kobayashi Pharmaceutical Co., Ltd.
- Kobayashi Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Full Year 2022